Redirecting anti-Vaccinia virus T cell immunity for cancer treatment by AAV-mediated delivery of the VV B8R gene

Cao, Dujuan; Song, Qianqian; Li, Junqi; Chard, Louisa S.; Jiang, Yuanyuan; Qin, Bin; Wang, Jianyao; Guo, Hongjian; Cheng, Zhenguo; Wang, Zhimin; Lemoine, Nicholas R.; Lu, Shuangshuang; Wang, Yaohe

doi:10.1016/j.omto.2022.04.008

Cited by 3 publications

(1 citation statement)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Apart from the discovery of novel metabolism-related therapeutic targets, optimizing the drug delivery approaches can also be taken into consideration. It has been reported that recombinant adeno-associated virus (rAAV) with a modified tumor-specific promoter can express genes specifically in tumor cells ( 162 ). Therefore, it would be possible to more precisely target some specific metabolic enzymes and intermediates in tumor cells via rAAV or an alternative delivery system, so as to avoid the contrary effect brought by the nuance of targeting the metabolic pathway between tumor cells and immune cells.…”

Section: Targeting Metabolism In Melanoma Immunologymentioning

confidence: 99%

Metabolic rewiring directs melanoma immunology

et al. 2022

View full text Add to dashboard Cite

Melanoma results from the malignant transformation of melanocytes and accounts for the most lethal type of skin cancers. In the pathogenesis of melanoma, disordered metabolism is a hallmark characteristic with multiple metabolic paradigms involved in, e.g., glycolysis, lipid metabolism, amino acid metabolism, oxidative phosphorylation, and autophagy. Under the driving forces of oncogenic mutations, melanoma metabolism is rewired to provide not only building bricks for macromolecule synthesis and sufficient energy for rapid proliferation and metastasis but also various metabolic intermediates for signal pathway transduction. Of note, metabolic alterations in tumor orchestrate tumor immunology by affecting the functions of surrounding immune cells, thereby interfering with their antitumor capacity, in addition to the direct influence on tumor cell intrinsic biological activities. In this review, we first introduced the epidemiology, clinical characteristics, and treatment proceedings of melanoma. Then, the components of the tumor microenvironment, especially different populations of immune cells and their roles in antitumor immunity, were reviewed. Sequentially, how metabolic rewiring contributes to tumor cell malignant behaviors in melanoma pathogenesis was discussed. Following this, the proceedings of metabolism- and metabolic intermediate-regulated tumor immunology were comprehensively dissertated. Finally, we summarized currently available drugs that can be employed to target metabolism to intervene tumor immunology and modulate immunotherapy.

show abstract

Section: Targeting Metabolism In Melanoma Immunologymentioning

confidence: 99%

Metabolic rewiring directs melanoma immunology

et al. 2022

View full text Add to dashboard Cite

show abstract

Preexisting immunity: Barrier or bridge to effective oncolytic virus therapy?

Groeneveldt¹,

Ende²,

Montfoort³

2023

Cytokine & Growth Factor Reviews

View full text Add to dashboard Cite

Engineering a broad-spectrum multi-epitope vaccine to combat emerging monkeypox virus by immunoinformatic approaches

Puagsopa,

Jumpalee,

Lohasupthawee

et al. 2024

Preprint

View full text Add to dashboard Cite

Monkeypox virus (MPXV), has caused 41,664 confirmed cases and five deaths in non-endemic regions, as reported by the World Health Organization (WHO). There is an urgent demand for effective vaccines to combat and prevent the spread of MPXV. Traditional vaccine development is low-throughput, expensive, time-consuming, and susceptible to reversion to virulence. As an alternative, a reverse vaccinology approach can be employed as a promising tool to design effective and safe vaccines against MPXV. Here, MPXV proteins associated with viral infection were analyzed for potential immunogenic epitopes to design multi-epitope vaccine constructs based on B-cell, CD4+, and CD8+ epitopes. Epitopes were selected based on allergenicity, antigenicity, and toxicity parameters. The prioritized epitopes were then combined via peptide linkers and N-terminally fused to various protein adjuvants, including PADRE, beta-defensin 3, 50S ribosomal protein L7/12, RS-09, and the cholera toxin B subunit (CTB). All vaccine constructs were further computationally validated for physicochemical properties, antigenicity potential, allergenicity, safety, solubility, and structural stability. The three-dimensional structure of the selected construct was also predicted. Moreover, molecular docking and molecular dynamics (MD) simulations between the vaccine and the TLR-4 immune receptor demonstrated a strong and stable interaction. The vaccine construct was codon-optimized for high expression in the E. coli platform and was finally cloned in silico into the pET21a(+) vector. Collectively, these results could represent innovative tools for vaccine formulation against MPXV and be transformative for other infectious diseases.

show abstract

Redirecting anti-Vaccinia virus T cell immunity for cancer treatment by AAV-mediated delivery of the VV B8R gene

Cited by 3 publications

References 42 publications

Metabolic rewiring directs melanoma immunology

Metabolic rewiring directs melanoma immunology

Preexisting immunity: Barrier or bridge to effective oncolytic virus therapy?

Engineering a broad-spectrum multi-epitope vaccine to combat emerging monkeypox virus by immunoinformatic approaches

Contact Info

Product

Resources

About